Eli Lilly’s Gateway Labs is going global, with the U.K. government announcing today that the nation will host the first European branch of the incubator program.

Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years.

Turnstone Biologics is reducing its head count by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate.

Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has decided that all roads now lead to bankruptcy.

The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data management platform.

OncoC4 is taking AcroImmune—and its in-house clinical manufacturing capabilities—under its wing in an all-stock merger.

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic.

Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the anti-OX40 antibody to significant improvements in symptoms. But, while the trial met its primary endpoints, the biotech still needs to make the case that there is a role for rocatinlimab in a market served by Dupixent.

Headlands Research, a clinical trial site network with locations across the U.S. and Canada, is launching its newest site on the U.S.-Mexico border in El Paso, Texas.

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners reporting positive top-line results in systemic lupus erythematosus (SLE) and outlining plans to start a second pivotal trial.